An interventional study of zinc, selenium, and L-tyrosine in SEPP1 and Placebo in Thyrotoxicosis, sponsored by S.LAB (SOLOWAYS). Not yet recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by S.LAB (SOLOWAYS) · Not applicable, Interventional, and Prevention
This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G/A SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant/breastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. With an estimated sample size of 150 participants per group, accounting for a 20% dropout rate, the trial seeks to demonstrate the supplement's potential in reducing thyrotoxicosis risk through a genetically-informed approach.
21 studies on the registry are indexed under Thyrotoxicosis; 5 are open to participants now.
Browse Thyrotoxicosis studies →S.LAB (SOLOWAYS) is the lead sponsor of 29 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: zinc, selenium, and L-tyrosine in SEPP1
Other: Placebo
zinc, selenium, and L-tyrosine in SEPP1 polymorphism
placebo comparator in SEPP1 polymorphism group
Percent change of Thyroid Peroxidase Antibodies (TPOAb) in subjects with r25191 SEPP1 polymorphism
Time frame: 6 months
Percent change in Thyroglobulin Antibodies (TgAb) in subjects with r25191 SEPP1 polymorphism
Time frame: 6 months
Free Thyroxine (Free T4) change in subjects with r25191 SEPP1 polymorphism
Time frame: 6 months
Free Triiodothyronine (Free T3) change in subjects with r25191 SEPP1 polymorphism
Time frame: 6 months
Thyroid Receptor Antibodies (TRAb) change in subjects with r25191 SEPP1 polymorphism
Time frame: 6 months
TSH Receptor Antibodies (TSHR-Ab) change in subjects with r25191 SEPP1 polymorphism
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
S.LAB (SOLOWAYS)